Twitter | Pretraživanje | |
Pretraživanje Osvježi
RheoSense 8 h
What's the cost of selecting the right ? Make sure you are aware of all of the tests possible and contact us if you need help getting recommended CROs and !
Reply Retweet Označi sa "sviđa mi se"
Dan Stanton 30. sij
Lack of good a factor for in investing $70-90m into internal PA gene therapy plant
Reply Retweet Označi sa "sviđa mi se"
CCRM 20. lip
CCRM is excited to launch a brand new initiative. We are answering your Qs on a variety of topics related to working with ...and if you don't know these acronyms, you should definitely check it out!
Reply Retweet Označi sa "sviđa mi se"
3PBiopharmaceuticals 19. ruj
We are so very proud to share the news about our approval!! This achievement positions us at the level of the most distinguished in the world and represents a very important breakthrough in the history of 3P.
Reply Retweet Označi sa "sviđa mi se"
53Biologics 13. pro
🌲🎁 Our is to provide to different companies, from start-ups to large companies, as well as to other , to help their products to reach the market
Reply Retweet Označi sa "sviđa mi se"
CM Life Science 19. kol
"Fear of innovation in the East will drive innovation in the West." Do Western CMOs need to 'up their game' to combat an increasingly Eastern-facing market? Read our latest article 👉
Reply Retweet Označi sa "sviđa mi se"
Cornell Stamoran 15. lis
Pharma : long time veteran observer and good friend Jim Miller reflects on 20+ years’ learnings at
Reply Retweet Označi sa "sviđa mi se"
Sterling Pharma 20. ožu
It's important for to be fully transparent when it comes to audits to ensure the correct quality is achieved. Read more: via
Reply Retweet Označi sa "sviđa mi se"
Generics bulletin 3. velj
Discover insider information from a recent roundtable discussion about the use of and what companies are looking for from them and much more. Download your copy here
Reply Retweet Označi sa "sviđa mi se"
Biotech Essentials 31. sij
‘Lack of good CDMOs’ factor for Krystal’s $90m gene therapy plant via
Reply Retweet Označi sa "sviđa mi se"
Onyx Scientific 27. stu
Although pharmaceutical companies choose to for different reasons, many businesses work with CROs, CMOs and because it can reduce the overall cost and risk of their project. Explore the other factors driving a surge in outsourcing here:
Reply Retweet Označi sa "sviđa mi se"
Johnson Matthey 19. stu
"Outsourcing is a very effective way for pharma companies to tap into additional formulation expertise.” Our Global VP Innovator Products and Solutions, Nick Shackley, examines the growing partnership between and in :
Reply Retweet Označi sa "sviđa mi se"
Parc Científic de Barcelona 4. stu
On 12 November we organise with the workshop 'Technologies for improving bioavalilability of poorly water-soluble ' by Dr A. Loxley, consultant of (), one of the world's leading ▶️ Don't miss it! 👍
Reply Retweet Označi sa "sviđa mi se"
Patheon 29. lis
. interviewed Michel Lagarde, Executive VP of Thermo Fisher Scientific, about the challenges are facing as the pharma and markets rapidly grow.
Reply Retweet Označi sa "sviđa mi se"
UnseenValue 23. lis
Odgovor korisniku/ci @unseenvalue
Ready to use next-gen technology platforms and shift in portfolios from large volumes but simple, to lower volumes but complex or orphan molecules or even the lack of approved capacity for complex/sterile drugs are some reasons the have started to feel real +ve traction.
Reply Retweet Označi sa "sviđa mi se"
CHEManager International 29. ruj
The continues to grow and is estimated at $1.5 trillion by 2021. An important driver is the trend to development and manufacturing to . We have asked executives working in this market to share their experiences.
Reply Retweet Označi sa "sviđa mi se"
Intalere 26. ruj
Supply chain digitization creates new revenue opportunities in the vaccine market via
Reply Retweet Označi sa "sviđa mi se"
Simon-Kucher 20. ruj
In order to capitalize on the trend to outsource product development and manufacturing, need to continuously optimize their strategy by establishing and enforcing a value-based pricing concept. Our experts commented for .
Reply Retweet Označi sa "sviđa mi se"
Life Science Integrates 12. ruj
In this panel at , we examine the future of vs and the implications for . Panellists represent , , , and . Find out more:
Reply Retweet Označi sa "sviđa mi se"
Johnson Matthey 5. kol
"A good CDMO is not just about doing what they are told – the best are also consultants and collaborators.” Our Global VP Innovator Products and Solutions, Nick Shackley, shares his insights on partnerships between and in :
Reply Retweet Označi sa "sviđa mi se"